I find this sentence rather interesting from the NR this am.
{{{{{{{{{{{ (RPE) cells for the treatment of diseases of the eye, to CHA Bio for development and commercialization exclusively in Korea. ACT received an """UNDISCLOSED""" up-front license fee. }}}}}}}}}}}}}}}
Oh No No No, The Company will be disclosing this "up-front" prior to the end of the 2nd qtr according to our CEO @ Advanced per the NR from Monday. :}
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.